A Phase 1 cellular immunotherapy study of intraventricularly administered autologous HER2‐targeted chimeric antigen receptor (HER2‐CAR) T cells in patients with brain and/or leptomeningeal metastases from HER2‐positive cancers. This evidence concerns the gene ERBB2 and cancer.